≥99% PURITY GUARANTEEDTHIRD-PARTY TESTEDSAME-DAY SHIPPING USACOA WITH EVERY ORDERFREE SHIPPING $200+
Back to Peptide ResearchSenolytic

FOXO4-DRI: Senolytic Peptide Targeting Senescent Cells

Research on FOXO4-DRI's mechanism of disrupting p53-FOXO4 interaction to selectively target senescent cells.

10 min readDecember 2025BioInfinity Lab

Research Use Only: All products on this site are for Research and Development use only. Products are not intended for human consumption. The statements made within this website have not been evaluated by the US Food and Drug Administration.

Abstract

FOXO4-DRI (FOXO4-D-retro-inverso) is a cell-permeable peptide designed to disrupt the interaction between forkhead box O4 (FOXO4) and p53 in senescent cells. The peptide uses D-amino acids in a retro-inverso configuration for enhanced protease resistance while maintaining binding function.

Molecular Background

  • Structure: 46 amino acids, all D-amino acids, retro-inverso configuration
  • Half-life: Over 48 hours in plasma due to protease resistance
  • Binding affinity: Kd approximately 0.3 µM for FOXO4
  • Cell penetration: Via arginine-rich motif

Proposed Mechanism

In senescent cells, the FOXO4-p53 interaction becomes stabilized, which prevents p53-mediated apoptosis. FOXO4-DRI is designed to:

  • Competitively displace p53 from FOXO4 binding
  • Restore nuclear p53 localization in senescent cells
  • Enable p53-dependent apoptosis pathways
  • Selectively affect senescent cells with the stabilized complex

Research Applications

  • Cellular Senescence Studies: Investigating senescent cell clearance mechanisms
  • Aging Research: Models of accelerated and natural aging
  • SASP Research: Senescence-associated secretory phenotype modulation
  • Protein-Protein Interaction: Studies of FOXO4-p53 complex disruption

Preclinical Research

Published studies have examined FOXO4-DRI in:

  • Progeroid mouse models
  • Naturally aged rodent models
  • Chemotherapy-induced senescence models
  • In vitro senescent fibroblast cultures

Selectivity

Research indicates specificity for senescent cells with the stabilized FOXO4-p53 complex. Studies report minimal effects on proliferating or quiescent cells lacking this interaction.

Current Research Status

As of December 2025, FOXO4-DRI remains in preclinical research. No human trials have been initiated. The evidence base comes primarily from the originating research laboratories, and independent replication is an area for future investigation.

Explore Our Research Peptides

Premium quality with ≥99% purity. COA included with every order.

Shop Now

Disclaimer: These Peptides are for Research use Only and not intended for Human Use. The information provided in this article is for educational purposes only and should not be construed as medical advice.